Index | iSTOXX® FactSet Breakthrough Healthcare |
Investment focus | Equity, World, Health Care, Social/Environmental |
Fund size | GBP 877 m |
Total expense ratio | 0.40% p.a. |
Replication | Physical (Optimized sampling) |
Legal structure | ETF |
Strategy risk | Long-only |
Sustainability | Yes |
Fund currency | USD |
Currency risk | Currency unhedged |
Volatility 1 year (in GBP) | 14.75% |
Inception/ Listing Date | 8 September 2016 |
Distribution policy | Accumulating |
Distribution frequency | - |
Fund domicile | Ireland |
Fund Provider | iShares |
Fund Structure | Open-ended Investment Company (OEIC) |
UCITS compliance | Yes |
Administrator | State Street Fund Services (Ireland) Limited |
Investment Advisor | |
Custodian Bank | State Street Custodial Services (Ireland) Limited |
Revision Company | Deloitte |
Fiscal Year End | 31 May |
Swiss representative | BlackRock Asset Management Schweiz AG |
Swiss paying agent | State Street Bank International GmbH, Munich, Zurich Branch |
Germany | 30% tax rebate |
Switzerland | ESTV Reporting |
Austria | Tax Reporting Fund |
UK | UK Reporting |
Indextype | Total return index |
Swap counterparty | - |
Collateral manager | Bank of New York Mellon|Euroclear|JP Morgan|State Street Bank |
Securities lending | Yes |
Securities lending counterparty | Barclays Bank Plc|Barclays Capital Securities Ltd.|BNP Paribas Arbitrage SNC|BNP Paribas SA|Citigroup Global Markets Ltd|Citigroup Inc|Credit Suisse Securities (Europe) Ltd.|Deutsche Bank AG|Goldman Sachs International|HSBC Bank Plc|J.P. Morgan Securities Plc|JP Morgan Chase & Co|Macquarie Bank Limited|Merrill Lynch International|Morgan Stanley & Co. International Plc|Nomura International Plc|Skandinaviska Enskilda Banken AB|Societe Generale SA|The Bank of Nova Scotia|UBS AG |
Sarepta Therapeutics | 1.99% |
argenx | 1.79% |
Gilead Sciences, Inc. | 1.65% |
Intuitive Surgical | 1.64% |
Edwards Lifesciences Corp. | 1.64% |
UCB SA | 1.63% |
Insulet | 1.63% |
Amgen, Inc. | 1.62% |
Neurocrine Biosciences, Inc. | 1.61% |
Biogen, Inc. | 1.60% |
United States | 64.90% |
Switzerland | 6.28% |
Japan | 4.87% |
South Korea | 3.60% |
Other | 20.35% |
Health Care | 96.04% |
Technology | 1.77% |
Other | 2.19% |
YTD | +2.89% |
1 month | +1.34% |
3 months | +1.34% |
6 months | +4.85% |
1 year | +4.85% |
3 years | -17.57% |
5 years | +20.28% |
Since inception (MAX) | +60.48% |
2023 | -3.45% |
2022 | -14.59% |
2021 | -4.81% |
2020 | +47.15% |
Volatility 1 year | 14.75% |
Volatility 3 years | 19.92% |
Volatility 5 years | 21.96% |
Return per risk 1 year | 0.33 |
Return per risk 3 years | -0.31 |
Return per risk 5 years | 0.17 |
Maximum drawdown 1 year | -14.09% |
Maximum drawdown 3 years | -35.82% |
Maximum drawdown 5 years | -38.73% |
Maximum drawdown since inception | -38.73% |
Listing | Trade Currency | Ticker | Bloomberg / iNAV Bloomberg Code | Reuters RIC / iNAV Reuters | Market Maker |
---|---|---|---|---|---|
gettex | EUR | 2B78 | - - | - - | - |
Stuttgart Stock Exchange | EUR | 2B78 | - - | - - | - |
Bolsa Mexicana de Valores | MXN | - | HEALN MM | HEALN.MX | |
Borsa Italiana | EUR | HEAL | HEAL IM INAVHEAE | HEAL.MI | |
Euronext Amsterdam | EUR | HEAL | HEAL NA | ||
London Stock Exchange | GBX | DRDR | DRDR LN | DRDR.L | |
London Stock Exchange | USD | HEAL | HEAL LN INAVHEAU | HEAL.L 0O64INAV.DE | |
London Stock Exchange | GBP | - | DRDR LN INAVHEAG | DRDR.L 0O62INAV.DE | |
SIX Swiss Exchange | USD | HEAL | HEAL SE INAVHEAU | HEAL.S 0O64INAV.DE | |
XETRA | EUR | 2B78 | 2B78 GY INAVHEAE | 2B78.DE 0O60INAV.DE |
Fund name | Fund Size in m € (AuM) | TER p.a. | Distribution | Replication |
---|---|---|---|---|
VanEck Genomics and Healthcare Innovators UCITS ETF A | 6 | 0.35% p.a. | Accumulating | Full replication |
Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF 1C | 3 | 0.30% p.a. | Accumulating | Full replication |